Full-Time

Senior Director

Compensation

Posted on 12/16/2025

Deadline 1/6/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$215k - $290k/yr

+ Bonus + Equity

Chicago, IL, USA

Hybrid

Three days on-site per week required.

Category
People & HR (1)
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Business, Human Resources, Finance, or other related field required; Advanced degree, CCP or CECP certification highly desired
  • Minimum 15 years of progressive experience in compensation, including executive compensation, equity programs, sales incentive compensation, market benchmarking and governance. Other relevant experience in HR such as HRIS, benefits and payroll a plus.
  • 5+ years directly leading a team. Experience building and scaling teams preferred.
  • Strong understanding of regulatory frameworks (FLSA, SEC, SOX, and tax compliance).
  • Experience in a publicly traded company in the biotechnology, pharmaceutical industries
  • Demonstrated ability to influence senior leaders and partner with Boards or Compensation Committees.
  • Acumen for development of automated systems
  • Proven success utilizing artificial intelligence to drive efficiencies and effectiveness in compensation management
  • Advanced Excel and HRIS proficiency (such as pivot tables, vlookups and advanced formulas)
Responsibilities
  • Lead the strategy development and administration of broad-based and executive compensation programs, including base pay, incentives, and equity.
  • Partner with the SVP of HR, executive management, and the Compensation Committee of the Board to design and recommend annual compensation strategies and policies.
  • Oversee annual compensation cycles (merit, bonus, and equity planning), ensuring alignment with business performance and market competitiveness.
  • Collaborate with Sales Operations team to ensure sales incentive compensation programs are effective and aligned to the Company’s overarching compensation philosophy.
  • Lead the development of educational tools and resources, including the facilitation of training on compensation programs for the organization.
  • Provide market analyses, benchmarking, and insights to guide talent and organizational decisions.
  • Ensure compliance with SEC, IRS, and other regulatory requirements related to executive compensation and disclosures (e.g., CD&A, proxy statements).
  • Oversee global payroll operations, ensuring timely and accurate processing for all employees.
  • Ensure compliance with federal, state, and international payroll tax laws and reporting requirements.
  • Partner with Finance, HRIS, and Legal to ensure robust controls and audit readiness for all payroll and related processes.
  • Drive process improvements, automation, and integration across HR, Finance, and systems platforms.
  • Partner with HRIS to enhance system capabilities that support compensation and payroll processes in Workday or similar systems.
  • Leverage data analytics to monitor pay equity, identify trends, and inform strategic decisions.
  • Maintain high standards of data integrity, confidentiality, and auditability across all compensation and payroll systems.
  • Lead and develop a high-performing team across the compensation and payroll function.
  • Establishes, directs, and allocates the necessary headcount and financial resources within the compensation and payroll function needed to support the company’s business strategy.
  • Collaborate closely with HR colleagues, finance, legal, sales operations.
  • Serve as a trusted advisor to senior management and the Board on compensation matters.
  • Serves as back-up to Benefits & HRIS colleagues
  • Participates in initiatives and/or other activities as required
Desired Qualifications
  • Advanced degree CCP or CECP certification highly desired
  • Experience building and scaling teams preferred
  • Acumen for development of automated systems
  • Proven success utilizing artificial intelligence to drive efficiencies and effectiveness in compensation management
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $50M in Q1 2026 with 60% therapy-naïve patient starts.
  • ADA 2025 Standards explicitly recommend ready-to-use glucagon formulations, validating Gvoke positioning.
  • XP-8121 Phase 3 initiation in late 2026 targets $1B–$3B peak sales by 2035.

What critics are saying

  • Eli Lilly Baqsimi captures 65% glucagon market share; Gvoke revenue flat at $20.8M Q1 2026.
  • Medicare Part D redesign favors lowest-price glucagon options, sustaining Gvoke revenue pressure indefinitely.
  • CEO Paul Edick retires August 1, 2026; leadership transition disrupts Recorlev commercial expansion momentum.

What makes Xeris Pharmaceuticals unique

  • XeriSol and XeriJect platforms enable room-temperature stable, ready-to-use injectable formulations without reconstitution.
  • Diversified rare disease portfolio: Recorlev, Gvoke, Keveyis, and Ogluo across endocrinology and neurology.
  • Achieved profitability in 2025 with $60M adjusted EBITDA and 44% revenue growth year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

ETF Daily News
Mar 29th, 2025
Cibc World Markets Corp Invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cibc World Markets Corp invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS).

INACTIVE